Diabetes of the brain: Computational approaches and interventional strategies

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 3, 2014, Pages 408-417

  Narasimhan, Kothandaraman ^a   Govindasamy, Meenakumari ^a   Gauthaman, Kalamegam ^a   Kamal, Mohammad A ^a   Abuzenadeh, Adel M ^a   Al Qahtani, Mohammed ^a   Kanagasabai, Rajaraman ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

Author keywords

Advanced glycation end products; Alzheimer's disease; Amyloid Protein; Diabetes mellitus; Inflammation; Insulin resistance

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMNESIA; ARTICLE; BIOLOGY; COMPUTER ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; NONHUMAN; OBESITY; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; BRAIN; CLASSIFICATION; COMPLICATION; COMPUTER ASSISTED DIAGNOSIS; PATHOLOGY;

ALZHEIMER DISEASE; BRAIN; DIABETES MELLITUS; DIAGNOSIS, COMPUTER-ASSISTED; HUMANS;

EID: 84897896981     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660156     Document Type: Article

References (101)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3): 137-152.
2. Selkoe DJ. Preventing Alzheimer's disease. Science 2012; 337(6101): 1488-1492.
3. Cacabelos R, Fernandez-Novoa L, Lombardi V, Corzo L, Pichel V, Kubota Y. Cerebrovascular risk factors in Alzheimer's disease: brain hemodynamics and pharmacogenomic implications. Neurol Res 2003; 25(6): 567-580.
4. Caldeira GL, Ferreira IL, Rego AC. Impaired transcription in Alzheimer's disease: key role in mitochondrial dysfunction and oxidative stress. J Alzheimers Dis 2013; 34(1): 115-131.
5. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 2009; 16(4): 809-821.
6. Liu B, Rasool S, Yang Z, et al. Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol 2009; 175(5): 2099-2110.
7. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. CNS Neurol Disord Drug Targets 2005; 4(3): 249-266.
8. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012; 72(1): 49-66.
9. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 2010; 1802;(1): 2-10.
10. Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann NY Acad Sci 1999; 893: 154-175.
11. Cunnane S, Nugent S, Roy M, et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 2011; 27(1): 3-20.
12. Engidawork E, Gulesserian T, Yoo BC, Cairns N, Lubec G. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 2001; 281(1): 84-93.
13. Zilkova M, Zilka N, Kovac A, et al. Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer's disease cellular model. J Alzheimers Dis 2011; 23(1): 161-9.
14. Gapp K, Woldemichael BT, Bohacek J, Mansuy IM. Epigenetic regulation in neurodevelopment and neurodegenerative diseases. Neuroscience 2012; 264C: 99-111.
15. Singh N, Chhillar N, Banerjee B, et al. Organochlorine pesticide levels and risk of Alzheimer's disease in north Indian population. Hum Exp Toxicol 2013; 32(1): 24-30.
16. Singh NK, Chhillar N, Banerjee BD, et al. Gene-environment interaction in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2012; 27(7): 496-503.
17. Whitmer RA, Gustafson DR, Barrett-Connor E, et al. Central obesity and increased risk of dementia more than three decades later. Neurology 2008; 71(14): 1057-1064.
18. Galani C, Schneider H. Prevention and treatment of obesity with lifestyle interventions: review and meta-analysis. Int J Public Health 2007; 52(6): 348-359.
19. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2008; 2(6): 1101-1113.
20. Cardoso S, Correia S, Santos RX, et al. Insulin is a two-edged knife on the brain. J Alzheimers Dis 2009; 18(3): 483-507.
21. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 2009; 16(4): 741-761.
22. Sima AA, Li ZG. Diabetes and Alzheimer's disease-is there a connection? Rev Diabet Stud 2006; 3(4): 161-8.
23. Jones A, Kulozik P, Ostertag A, Herzig S. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J Alzheimers Dis 2009; 16(4): 787-808.
24. Loy CT, Twigg SM. Growth factors, AGEing, and the diabetes link in Alzheimer's disease. J Alzheimers Dis 2009; 16(4): 823-831.
25. Lefebvre T, Dehennaut V, Guinez C, et al. Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2010; 1800;(2): 67-79.
26. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 2010; 67(6): 505-512.
27. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011; 39(4): 891-7.
28. Park SA. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 2011; 7(1): 10-8.
29. Botero LE, Toro AE, Patino AJ, et al. Diabetes mellitus in patients with Alzheimer's disease: clinical description and correlation with the APOE genotype in a sample population from the province of Antioquia, Colombia. Biomedica 2012; 32(2): 239-251.
30. Priyadarshini M, Kamal MA, Greig NH, et al. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
31. Frolich L, Blum-Degen D, Riederer P, Hoyer S. A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann NY Acad Sci 1999; 893: 290-3.
32. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8(3): 247-268.
33. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulinlike growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
34. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012; 9(1): 35-66.
35. Moreira PI. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 2012; 30(Suppl 2): S199-S215.
36. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17(1): 27-45.
37. Watson GS, Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 2006; 245(1-2): 21-33.
38. Ghasemi R, Dargahi L, Haeri A, et al. Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders. Mol Neurobiol 2013; 47(3): 1045-1065.
39. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104(4): 517-529.
40. Horwood JM, Dufour F, Laroche S, Davis S. Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 2006; 23(12): 3375-3384.
41. Vignini A, Giulietti A, Nanetti L, et al. Alzheimer's disease And Diabetes: New Insights and Unifying Therapies. Curr Diabetes Rev 2013; 9(3): 218-227.
42. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122(4): 1316-1338.
43. de la Monte SM. Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis 2012; 30(Suppl 2): S231-S249.
44. de la Monte SM, Tong M, Lawton M, Longato L. Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment. Mol Neurodegener 2009; 4: 54.
45. Tschritter O, Preissl H, Hennige AM, et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA 2006; 103(32): 12103-8.
46. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009; 42(8): 475-481.
47. Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B. Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer's disease links numerous treatment rationales. Pharmacol Rev 2012; 64(4): 1004-1026.
48. Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer's disease. Int J Mol Sci 2012; 13(10): 12629-12655.
49. Liu F, Shi J, Tanimukai H, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 2009; 132(Pt 7): 1820-1832.
50. Jhamandas JH, Li Z, Westaway D, et al. Actions of beta-amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol 2011; 178(1): 140-9.
51. Deng Y, Li B, Liu Y, et al. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 2009; 175(5): 2089-2098.
52. Currais A, Prior M, Lo D, et al. Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice. Aging Cell 2012; 11(6): 1017-1026.
53. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75(9): 764-770.
54. Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012; 78(14): 1043-1050.
55. Valente T, Gella A, Fernandez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37(1): 67-76.
56. Desire L, Blondiaux E, Carriere J, et al. Blood Transcriptomic Biomarkers of Alzheimer's Disease Patients Treated with EHT 0202. J Alzheimers Dis 2012; 34(2): 469-483.
57. Chandra V, Pandav R. Gene-environment interaction in Alzheimer's disease: a potential role for cholesterol. Neuroepidemiology 1998; 17(5): 225-232.
58. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009; 28(1): 75-80.
59. Reitz C, Tang MX, Schupf N, et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 2010; 67(12): 1491-7.
60. Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66(3): 343-8.
61. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011; 77(5): 461-8.
62. Verri M, Pastoris O, Dossena M, et al. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Int J Immunopathol Pharmacol 2012; 25(2): 345-353.
63. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals and brain aging. Clin Geriatr Med 2004; 20(2): 329-359.
64. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 2011; 15(9): 1807-1821.
65. Migliore L, Fontana I, Colognato R, et al. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 2005; 26(5): 587-595.
66. Pratico D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. Neurobiol Aging 2005; 26(5): 581-3.
67. Chami L, Buggia-Prevot V, Duplan E, et al. Nuclear factor-kappaB regulates betaAPP and beta-and gamma-secretases differently at physiological and supraphysiological Abeta concentrations. J Biol Chem 2012; 287(29): 24573-24584.
68. Vom Berg J, Prokop S, Miller KR, et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012; 18(12): 1812-9.
69. Tichauer JE, von Bernhardi R. Transforming growth factor-beta stimulates beta amyloid uptake by microglia through Smad3-dependent mechanisms. J Neurosci Res 2012; 90(10): 1970-1980.
70. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012; 122(4): 1339-1353.
71. Ewald CY, Raps DA, Li C. APL-1: the Alzheimer's Amyloid precursor protein in Caenorhabditis elegans, modulates multiple metabolic pathways throughout development. Genetics 2012; 191(2): 493-507.
72. Ewald CY, Li C. Caenorhabditis elegans as a model organism to study APP function. Exp Brain Res 2012; 217(3-4): 397-411.
73. Hiltunen M, Khandelwal VK, Yaluri N, et al. Contribution of genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 transgenic mice. J Cell Mol Med 2012; 16(6): 1206-1222.
74. Lane RF, St George-Hyslop P, Hempstead BL, et al. Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes. J Neurosci 2012; 32(41): 14080-6.
75. Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 2010; 9(4): 399-417.
76. Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A. Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis 2011; 2011: 832379.
77. Lester-Coll N, Rivera EJ, Soscia SJ, et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006; 9(1): 13-33.
78. Lukiw WJ. NF-kappaB-regulated, proinflammatory miRNAs in Alzheimer's disease. Alzheimers Res Ther 2012; 4(6): 47.
79. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005; 7(1): 45-61.
80. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009; 1792;(5): 482-496.
81. Benedict C, Hallschmid M, Hatke A, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29(10): 1326-1334.
82. Frost S, Martins RN, Kanagasingam Y. Ocular biomarkers for early detection of Alzheimer's disease. J Alzheimers Dis 2010; 22(1): 1-16.
83. Guo L, Duggan J, Cordeiro MF. Alzheimer's disease and retinal neurodegeneration. Curr Alzheimer Res 2010; 7(1): 3-14.
84. Alexandrov PN, Pogue A, Bhattacharjee S, Lukiw WJ. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer's disease. Neuroreport 2011; 22(12): 623-7.
85. Howlett DR, Bate ST, Collier S, et al. Characterisation of amyloidinduced inflammatory responses in the rat retina. Exp Brain Res 2011; 214(2): 185-197.
86. Bitel CL, Kasinathan C, Kaswala RH, Klein WL, Frederikse PH. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis 2012; 32(2): 291-305.
87. Chiu K, Chan TF, Wu A, et al. Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina? Age(Dordr) 2012; 34(3): 633-649.
88. Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M. Alzheimer's disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. Neurodegener Dis 2012; 10(1-4): 285-293.
89. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. Faseb J 2004; 18(7): 902-4.
90. Kohjima M, Sun Y, Chan L. Increased food intake leads to obesity and insulin resistance in the tg2576; Alzheimer's disease mouse model. Endocrinology 2010; 151(4): 1532-1540.
91. Bajic VB, Veronika M, Veladandi PS, et al. Dragon Plant Biology Explorer. A text-mining tool for integrating associations between genetic and biochemical entities with genome annotation and biochemical terms lists. Plant Physiol 2005; 138(4): 1914-1925.
92. Baker CJ, Kanagasabai R, Ang WT, et al. Towards ontologydriven navigation of the lipid bibliosphere. BMC Bioinform 2008; 9(Suppl 1): S5.
93. Rajapakse M, Kanagasabai R, Ang WT, et al. Ontology-centric integration and navigation of the dengue literature. J Biomed Inform 2008; 41(5): 806-815.
94. Kanagasabai R, Choo KH, Ranganathan S, Baker CJ. A workflow for mutation extraction and structure annotation. J Bioinform Comput Biol 2007; 5(6): 1319-1337.
95. de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci 2012; 4: 1582-1605.
96. Qin W, Haroutunian V, Katsel P, et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol 2009; 66(3): 352-361.
97. Mandel SA, Weinreb O, Amit T, Youdim MB. Molecular mechanisms of the neuroprotective/neurorescue action of multitarget green tea polyphenols. Front Biosci 2012; 4: 581-598.
98. Kuljis RO, Salkovic-Petrisic M. Dementia, diabetes, Alzheimer's disease, and insulin resistance in the brain: progress, dilemmas, new opportunities, and a hypothesis to tackle intersecting epidemics. J Alzheimers Dis 2011; 25(1): 29-41.
99. Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013; 34: 1581-1588.
100. Pratico D. Alzheimer's disease and the quest for its biological measures. J Alzheimers Dis 2013; 33 Suppl 1: S237-S241.
101. Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J Neurosci 2012; 32(14): 4705-4715.